127 related articles for article (PubMed ID: 32681657)
1. Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.
Miyagi D; Chen WY; Chen BJ; Su YZ; Kuo CC; Karube K; Chuang SS
Cytopathology; 2020 Nov; 31(6):602-606. PubMed ID: 32681657
[No Abstract] [Full Text] [Related]
2. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
3. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
SahBandar IN; Sy CB; van den Akker T; Kim D; Geyer JT; Chadburn A; Cesarman E; Inghirami G; Allan JN; Siddiqui MT; Ouseph MM
Pathobiology; 2023; 90(5):356-364. PubMed ID: 36996787
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia.
Ng IK; Ruparel M; Chan EH; Khoo KL
J R Coll Physicians Edinb; 2024 Mar; 54(1):44-47. PubMed ID: 38486345
[TBL] [Abstract][Full Text] [Related]
5. HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.
Christe L; Veloza L; Gros L; Bisig B; Blum S; Hewer E; de Leval L
Diagn Cytopathol; 2022 Dec; 50(12):E351-E356. PubMed ID: 35916333
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of the cytopathological features of primary effusion lymphoma and human herpes virus 8-related lymphoproliferative disorders.
Verga L; Leni D; Cazzaniga G; Crosta S; Seminati D; Rossi M; L'Imperio V; Pagni F
Cytopathology; 2020 Nov; 31(6):541-546. PubMed ID: 32171033
[TBL] [Abstract][Full Text] [Related]
7. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
[TBL] [Abstract][Full Text] [Related]
8. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
9. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
10. Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case.
Juneja R; Dhamija G; Dadu T; Handoo A
Indian J Pathol Microbiol; 2016; 59(2):259-60. PubMed ID: 27166066
[No Abstract] [Full Text] [Related]
11. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia.
Imamura M
Geriatr Gerontol Int; 2016 Jun; 16(6):768-70. PubMed ID: 27246579
[No Abstract] [Full Text] [Related]
13. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Hickman K; Diaz E; Graham R; Adams R; Ngwube A
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e665-e667. PubMed ID: 31688632
[TBL] [Abstract][Full Text] [Related]
15. Unusual case of dasatinib-associated acute bilateral hyphemas leading to blindness in a patient with chronic myeloid leukaemia.
Sharma S; Garg N; Ghiuzeli CM
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30150345
[TBL] [Abstract][Full Text] [Related]
16. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Hughes TP; Laneuville P; Rousselot P; Snyder DS; Rea D; Shah NP; Paar D; Abruzzese E; Hochhaus A; Lipton JH; Cortes JE
Haematologica; 2019 Jan; 104(1):93-101. PubMed ID: 30093398
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
Fujimi A; Nagamachi Y; Yamauchi N
Ann Hematol; 2018 Jun; 97(6):1103-1104. PubMed ID: 29404720
[No Abstract] [Full Text] [Related]
18. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
Keskin D; Sadri S; Eskazan AE
Drug Des Devel Ther; 2016; 10():3355-3361. PubMed ID: 27784993
[TBL] [Abstract][Full Text] [Related]
19. The role of dasatinib in the management of chronic myeloid leukemia.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():773-9. PubMed ID: 25709401
[TBL] [Abstract][Full Text] [Related]
20. Interstitial pneumonitis associated with dasatinib: two case reports and literature review.
Ito Y; Tanigawa M; Iwamoto K; Nigi A; Itani H; Kondo S; Tokui T; Usui E; Tamaki S
Respir Investig; 2019 Sep; 57(5):506-509. PubMed ID: 31311724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
